Home/Filings/4/0001213900-24-084830
4//SEC Filing

Ehrlich Christopher B 4

Accession 0001213900-24-084830

CIK 0001870404other

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 9:53 PM ET

Size

10.8 KB

Accession

0001213900-24-084830

Insider Transaction Report

Form 4
Period: 2024-09-25
Ehrlich Christopher B
DirectorChairman and CEO
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-09-30572,1820 total
    Exercise: $1.77Exp: 2034-03-24Common Stock (572,182 underlying)
  • Exercise/Conversion

    Common Stock

    2024-09-25+5,312,9835,791,808 total
  • Exercise/Conversion

    Series A Convertible Preferred Stock

    2024-09-25$1000.00/sh275$275,0000 total
    Common Stock (5,312,983 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    3,600
Footnotes (2)
  • [F1]On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date.
  • [F2]Represents the forfeiture of employee stock options in connection with the Reporting Person's appointment as Chief Executive Officer of the Issuer.

Documents

1 file

Issuer

CERO THERAPEUTICS HOLDINGS, INC.

CIK 0001870404

Entity typeother

Related Parties

1
  • filerCIK 0001293973

Filing Metadata

Form type
4
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 9:53 PM ET
Size
10.8 KB